Document Detail

Impact of paravalvular leakage on outcome in patients after transcatheter aortic valve implantation.
MedLine Citation:
PMID:  22917458     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The aim of this study was to evaluate the performance of the aortic regurgitation (AR) index as a new hemodynamic parameter in an independent transcatheter aortic valve implantation (TAVI) cohort and validate its application.
BACKGROUND: Increasing evidence associates more-than-mild periprosthetic aortic regurgitation (periAR) with increased mortality and morbidity; therefore precise evaluation of periAR after TAVI is essential. The AR index has been proposed recently as a simple and reproducible indicator for the severity of periAR and predictor of associated mortality.
METHODS: The severity of periAR was evaluated by echocardiography, angiography, and periprocedural measurement of the dimensionless AR index = ([diastolic blood pressure - left ventricular end-diastolic pressure]/systolic blood pressure) × 100. A cutoff value of 25 was used to identify patients at risk.
RESULTS: One hundred twenty-two patients underwent TAVI by use of either the Medtronic CoreValve (Medtronic, Minneapolis, Minnesota) (79.5%) or the Edwards-SAPIEN bioprosthesis (Edwards Lifesciences, Irvine, California) (20.5%). The AR index decreased stepwise from 29.4 ± 6.3 in patients without periAR (n = 26) to 28.0 ± 8.5 with mild periAR (n = 76), 19.6 ± 7.6 with moderate periAR (n = 18), and 7.6 ± 2.6 with severe periAR (n = 2) (p < 0.001). Patients with AR index <25 had a significantly increased 1-year mortality rate compared with patients with AR index ≥ 25 (42.3% vs. 14.3%; p < 0.001). Even in patients with none/mild periAR, the 1-year mortality risk could be further stratified by an AR index <25 (31.3% vs. 14.3%; p = 0.04).
CONCLUSIONS: The validity of the AR index could be confirmed in this independent TAVI cohort and provided prognostic information that was complementary to the severity of AR.
Mariuca Vasa-Nicotera; Jan-Malte Sinning; Derek Chin; Tiong Keng Lim; Tomasz Spyt; Hasan Jilaihawi; Eberhard Grube; Nikos Werner; Georg Nickenig; Jan Kovac
Related Documents :
3278028 - Hypertensive response to levonordefrin in a patient receiving propranolol: report of case.
1346558 - Safety of pyridostigmine in hypertensive patients receiving beta blockers.
3946248 - Hemodynamics of metoprolol and pindolol in systemic hypertension with particular refere...
11998 - A comparison of the actions of ici66082 and propranolol on cardiac and peripheral beta-...
547658 - Cardiovascular studies during induction with minaxolone.
19617228 - High-frequency oscillatory ventilation (hfov) and airway pressure release ventilation (...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  5     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-24     Completed Date:  2013-01-28     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  858-65     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Aortic Valve / surgery*
Aortic Valve Insufficiency / etiology*
Heart Valve Prosthesis Implantation / adverse effects*,  methods*
Prospective Studies
Severity of Illness Index
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reduction in treatment times through formalized data feedback: results from a prospective multicente...
Next Document:  Radiation dose reduction in the invasive cardiovascular laboratory: implementing a culture and philo...